Center For Cancer and Blood Disorders

Summary

Center For Cancer and Blood Disorders is a medical facility located in Bethesda, Maryland. This center is recognized for care of Multiple Myeloma, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Center For Cancer and Blood Disorders is involved with conducting 151 clinical trials across 115 conditions. There are 2 research doctors associated with this hospital, such as Mark Goldstein, MD and Ralph Boccia.

Top PIs

Clinical Trials running at Center For Cancer and Blood Disorders

Multiple Myeloma

Myelofibrosis

Colorectal Cancer

Male Pattern Baldness

Primary Myelofibrosis

Minimal Residual Disease

Diffuse Large B-Cell Lymphoma

Non-Hodgkin's Lymphoma

Pancreatic Cancer

Skin Cancer

ABBV-383

for Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Recruiting

2 awards

Phase 3

4 criteria

Tec-DR and Tal-DR

for Multiple Myeloma

This trial is testing two new drug combinations to see if they work better than the current standard treatment for multiple myeloma. The new treatments aim to help the immune system find and destroy cancer cells more effectively.

Recruiting

2 awards

Phase 3

5 criteria